Synthesis of Thermoplastic Poly(2‐methoxyethyl acrylate)‐Based Polyurethane by RAFT and Condensation Polymerization

Abstract

Thermoplastic solid poly(2‐methoxyethyl acrylate) (PMEA)‐based polyurethane (PU) is synthesized through the reversible addition−fragmentation chain transfer (RAFT) polymerization and the condensation polymerization, using hydroxyl‐terminated RAFT reagents and diisocyanate, respectively. Neat PMEA is a promising antithrombogenic liquid used in the medical fields. The thermoplastic property of the solid PMEA‐based PU due to hydrogen bonding is confirmed by the dynamic mechanical analysis (DMA) at temperature below 72 °C. The antithrombogenic property of PMEA‐based PU is also analyzed by the platelet adhesion test. The number of platelets on PMEA‐based PU is 17 cells per unit area, which is smaller than that on the fluorinated diamond‐like carbon (F‐DLC), a well‐known highly antithrombogenic material. It is concluded that a newly synthesized PMEA‐based PU exhibits thermoplastic characteristics with excellent antithrombogenicity.

Assessment of the Anti-Thrombogenic Activity of Polyurethane Starch Composites

“…However, the lack of knowledge about the thrombogenicity activity of polyurethanes has led to its study to improve its long-term anti-thrombotic response. Chemical backbone modifications [ 13 , 14 , 15 ], surface modifications [ 16 , 17 , 18 ], and the inclusion of fillers in the polymeric matrix [ 19 , 20 ] have been addressed. However, the characterization of composites with other assays different than hemolysis and cell viability is poorly reported.…”